Archive - June 2021
FDA lifts clinical hold on bluebird bio’s LentiGlobin studies
J&J exits $1.6bn blood cancer drug licensing deal with argenx
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
Entry closing next Friday for CROY 2021
New research identifies single biomarker that can indicate underlying neurodegeneration
SMC backs five new medicines for NHS use
NICE recommends Tecentriq for first-line NSCLC
Biogen, Eisai’s Alzheimer’s drug aducanumab makes history with US approval
